Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX).

被引：0
|
作者：
Agafitei, RD [1 ]
Schneider, S [1 ]
Iqbal, S [1 ]
Yang, D [1 ]
Groshen, S [1 ]
Lenz, HJ [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3600
引用
收藏
页码：270S / 270S
页数：1
相关论文
共 50 条
  • [1] Pilot trial of 5-FU/oxaliplatin (CIFOX) for patients with metastatic colorectal cancer who progressed on 5-FU/LV/CPT-11 (IFL).
    Aparicio, A
    Iqbal, S
    Yang, D
    Groshen, S
    Park, D
    Garcia, A
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 312S - 312S
  • [2] Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.
    Yun, J
    Zhang, W
    Park, D
    Yang, D
    Press, O
    Gordon, M
    Mallik, N
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 249S - 249S
  • [3] Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer
    Mitchell, EP
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (12): : 30 - 32
  • [4] Oxaliplatin/5-FU chemotherapy without leucovorin in metastatic colorectal cancer.
    Shim, BY
    Cho, HJ
    Yang, JM
    Kim, HJ
    Kim, JK
    Kim, HK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 302S - 302S
  • [5] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    J B Kjersem
    M Thomsen
    T Guren
    J Hamfjord
    G Carlsson
    B Gustavsson
    T Ikdahl
    G Indrebø
    P Pfeiffer
    O Lingjærde
    K M Tveit
    Y Wettergren
    E H Kure
    [J]. The Pharmacogenomics Journal, 2016, 16 : 272 - 279
  • [6] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    Kjersem, J. B.
    Thomsen, M.
    Guren, T.
    Hamfjord, J.
    Carlsson, G.
    Gustavsson, B.
    Ikdahl, T.
    Indrebo, G.
    Pfeiffer, P.
    Lingjaerde, O.
    Tveit, K. M.
    Wettergren, Y.
    Kure, E. H.
    [J]. PHARMACOGENOMICS JOURNAL, 2016, 16 (03): : 272 - 279
  • [7] Compliance and toxicity in metastatic colorectal carcinoma patients treated with capecitabine versus 5-FU associated with oxaliplatin or irinotecan
    Raimondi, C.
    Longo, F.
    Tomao, S.
    Ricciardi, S.
    Rosati, S.
    Messina, C. G. M.
    Cerbone, L.
    Spalletta, B.
    Russillo, M.
    Di Seri, M.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI43 - XI43
  • [8] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)
    Amoroso, Vito
    Ferrari, Vittorio
    Valcamonico, Francesca
    Vassalli, Lucia
    Simoncini, Edda
    Grisanti, Salvatore
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63
  • [9] Prospective, multi-center study of pharmacokinetically-guided dosing of fluorouracil (5-FU) in metastatic colorectal cancer patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens
    Jaehde, U.
    Kunzmann, V
    Link, K.
    Holdenrieder, S.
    Bertsch, T.
    Mueller, L.
    Ko, Y. -D
    Stoetzer, O. J.
    Suttmann, I
    Braess, J.
    Roessler, M.
    Moritz, B.
    Kraff, S.
    Fritsch, A.
    Miller, M. C.
    Salamone, S. J.
    Wilhelm, M.
    [J]. Oncology Research and Treatment, 2015, 38 : 207 - 207
  • [10] Intratumoral mRNA levels predict clinical outcome in patients with metastatic colorectal cancer treated in a prospective clinical trial with 5-FU and oxaliplatin.
    Yang, D.
    Vallböhmer, D.
    Zhang, W.
    Iqbal, S.
    El-Khoueiry, A.
    Gordon, M.
    Park, D.
    Azuma, M.
    Groshen, S.
    Danenberg, K. D.
    Lenz, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 543S - 543S
12345